Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up

British Journal of Haematology

Volumn 163, Issue 5, 2013, Pages 674-676

  Gallipoli, Paolo ^a   Stobo, Jon ^a   Heaney, Nicholas ^b   Nicolini, Franck E ^c   Clark, Richard ^d   Wilson, George ^a   Tighe, Jane ^e   Mclintock, Lorna ^f   Hughes, Timothy ^g   Michor, Franziska ^h   Paul, James ^a   Drummond, Mark ^b   Holyoake, Tessa L ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^e ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^f VICTORIA HOSPITAL   (United Kingdom)

^g SA Pathology ^*  (Australia)

^h DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

BCR ABL1; Chronic myeloid leukaemia; Stem cells; Therapy; Trials

Indexed keywords

BCR ABL PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

BCR ABL1 GENE; CANCER RISK; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; FOLLOW UP; LETTER; MULTIPLE CYCLE TREATMENT; ONCOGENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE;

BCR-ABL1; CHRONIC MYELOID LEUKAEMIA; STEM CELLS; THERAPY; TRIALS;

BENZAMIDES; CELL CYCLE; DRUG SUBSTITUTION; DRUG SYNERGISM; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PULSE THERAPY, DRUG; PYRIMIDINES; THIAZOLES; TREATMENT OUTCOME;

EID: 84887536827     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12532     Document Type: Letter

References (6)

1. Chomel, J.C., Bonnet, M.L., Sorel, N., Bertrand, A., Meunier, M.C., Fichelson, S., Melkus, M., Bennaceur-Griscelli, A., Guilhot, F. & Turhan, A.G. (2011) Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood, 118, 3657-3660.
2. Drummond, M.W., Heaney, N., Kaeda, J., Nicolini, F.E., Clark, R.E., Wilson, G., Shepherd, P., Tighe, J., McLintock, L., Hughes, T. & Holyoake, T.L. (2009) A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia, 23, 1199-1201.
3. Foo, J., Drummond, M.W., Clarkson, B., Holyoake, T. & Michor, F. (2009) Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. Plos Computational Biology, 5, e1000503.
4. Graham, S.M., Jorgensen, H.G., Allan, E., Pearson, C., Alcorn, M.J., Richmond, L. & Holyoake, T.L. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 99, 319-325.
5. Hamilton, A., Helgason, G.V., Schemionek, M., Zhang, B., Myssina, S., Allan, E.K., Nicolini, F.E., Muller-Tidow, C., Bhatia, R., Brunton, V.G., Koschmieder, S. & Holyoake, T.L. (2012) Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood, 119, 1501-1510.
6. Jorgensen, H.G., Copland, M., Allan, E.K., Jiang, X., Eaves, A., Eaves, C. & Holyoake, T.L. (2006) Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clinical Cancer Research, 12, 626-633.